Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857714 · ClinicalTrials.gov registry record · NA
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00857714: Clinical Trial NA study, sponsored by Indiana University.
NCT00857714 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00857714, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.
Primary Outcome
Number of patients where gene signature was obtained. This was used to identify gene signature that denotes effect of lapatinib therapy in breast cancer cell lines and to assess effect of lapatinib therapy in patients with ductal carinoma in situ of the breast using the gene signature developed as a surrogate marker.
Interventions
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-08 |
| Phase | NA |
Why NCT00857714 stopped before completion
NCT00857714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which lapatinib is the first listed.
NCT00857714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00857714 about?
NCT00857714 is a clinical study titled "Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast". The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.
What is the current status of trial NCT00857714?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2009-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00857714?
The interventions under investigation include: lapatinib (DRUG).
Who is sponsoring clinical trial NCT00857714?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00857714's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia